NEW YORK (S&P Global Ratings) July 29, 2020--S&P Global Ratings today said that medical device developer, manufacturer, and marketer Boston Scientific Corp.'s (BBB-/Stable/A-3) recently announced second-quarter 2020 operating results are consistent with our expectations. The company's business continued to be materially affected by the coronavirus pandemic, which led to a 23.9% year-over-year revenue decline. The reduction in Boston Scientific's sales reflected declining volumes in all segments due to the mass deferral of elective procedures in the second quarter. However, the company noted that its procedure volume trends improved significantly over the course of the quarter. Our ratings and stable outlook on Boston Scientific remain unchanged and reflect our expectation that its procedure volumes will continue to improve over the next
